Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CONX - Corgenix Medical's Trading Volume Exceeded Daily Average by +208.93%
Alert Triggered for Corgenix Medical Corp
CONX is up $0.02 or 5.21% to $0.49 on heavy volume that exceeded its daily average by +208.93%. This performance is better than the broader averages as the S&P 500 is down -0.41% on the day.
Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Corgenix Medical Corp.
$CONX - Corgenix Medical's Trading Volume Exceeded Daily Average by +208.93%
Alert Triggered for Corgenix Medical Corp
CONX is up $0.02 or 5.21% to $0.49 on heavy volume that exceeded its daily average by +208.93%. This performance is better than the broader averages as the S&P 500 is down -0.41% on the day.
Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Corgenix Medical Corp.
$IMSC - Implant Sciences CEO Invited to Attend Inaugural U.S.-Africa Business Forum by U.S. Department of Commerce Glenn Bolduc joins President Barack Obama, African leaders, and leading U.S. and African CEOs in an event focused on strengthening commercial and business ties between the U.S. and Africa - Worldnews.com:
http://shar.es/LioLY
$IMSC - Implant Sciences CEO Invited to Attend Inaugural U.S.-Africa Business Forum by U.S. Department of Commerce Glenn Bolduc joins President Barack Obama, African leaders, and leading U.S. and African CEOs in an event focused on strengthening commercial and business ties between the U.S. and Africa - Worldnews.com:
http://shar.es/LioLY
$IMSC - Implant Sciences: The Most Trusted Name in Expolosive Trace Detection:
http://www.whitehouse.gov/sites/default/files/docs/usabf_attendeelistbycountry_july31.pdf
IMSC - Implant Sciences: The Most Trusted Name in Explosive Trace Detection.
$CONX - Corgenix Medical Reached a New 52 Week High at $0.48
Alert Triggered for Corgenix Medical Corp
CONX rose 22.76% to a new 52 week high of $0.48. During the last 52 weeks, CONX's price has ranged from $0.17 on September 24, 2013 to today's high of $0.48.
Additionally, over the last 12 months, CONX has increased 152.23% while its peers in the Health Care Equipment industry increased 15.21%.
Please note you will receive only one "New 52 Week High" alert per day for Corgenix Medical Corp.
$CONX - Corgenix Medical Reached a New 52 Week High at $0.48
Alert Triggered for Corgenix Medical Corp
CONX rose 22.76% to a new 52 week high of $0.48. During the last 52 weeks, CONX's price has ranged from $0.17 on September 24, 2013 to today's high of $0.48.
Additionally, over the last 12 months, CONX has increased 152.23% while its peers in the Health Care Equipment industry increased 15.21%.
Please note you will receive only one "New 52 Week High" alert per day for Corgenix Medical Corp.
$IMSC - Implant Sciences (anti-terrorist security) and $CONX - Corgenix Medical (Ebola virus test) displaying impressive upmoves.
$IMSC - Implant Sciences (anti-terrorist security) and $CONX - Corgenix Medical (Ebola virus test) displaying impressive upmoves.
$CONX - Corgenix Medical / Ebola Virus-Related News:
The Peace Corps says it is temporarily removing its 340 volunteers from Liberia, Sierra Leone and Guinea due to an outbreak of the deadly Ebola virus.
A spokeswoman for the group said two volunteers have been isolated after coming in contact with someone who later died from Ebola.
Separately, two American aid workers working with Samaritan's Purse who were infected with Ebola "have shown a slight improvement," according to that group.
Follow complete coverage of breaking news on CNN.com, CNN TV and CNN Mobile.
$CONX - Corgenix Medical / Ebola Virus-Related News:
The Peace Corps says it is temporarily removing its 340 volunteers from Liberia, Sierra Leone and Guinea due to an outbreak of the deadly Ebola virus.
A spokeswoman for the group said two volunteers have been isolated after coming in contact with someone who later died from Ebola.
Separately, two American aid workers working with Samaritan's Purse who were infected with Ebola "have shown a slight improvement," according to that group.
Follow complete coverage of breaking news on CNN.com, CNN TV and CNN Mobile.
What date was the interview?
$IMSC - Implant Sciences Reached a New 52 Week High at $1.30
Edit: $1.32
Alert Triggered for Implant Sciences Corp
IMSC rose 4.00% to a new 52 week high of $1.30. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.30.
Additionally, over the last 12 months, IMSC has increased 12.07% while its peers in the Electronic Equipment & Instruments industry increased 15.07%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
$IMSC - Implant Sciences Reached a New 52 Week High at $1.30
Edit: $1.32
Alert Triggered for Implant Sciences Corp
IMSC rose 4.00% to a new 52 week high of $1.30. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.30.
Additionally, over the last 12 months, IMSC has increased 12.07% while its peers in the Electronic Equipment & Instruments industry increased 15.07%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
$CONX - Corgenix Medical Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Ebola research award and Lassa fever oral abstract highlight Corgenix infectious disease diagnostic test development capabilities
CHICAGO, Jul 30, 2014 (BUSINESS WIRE) -- Corgenix Medical Corporation CONX+4.76% has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract “ Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection ,” presented at the conference by Corgenix Research Associate Abby Jones, M.S.
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point of Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.
“We’re pleased to accept this prestigious award, and we must also recognize our academic, research and industry partners at the Viral Hemorrhagic Fever Consortium who have helped to make this possible,” said Douglass Simpson, Corgenix President and CEO. “We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats.”
Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV® rapid diagnostic test for the Lassa fever virus.
Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it’s clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg.
On Thursday, July 31, 2014, Corgenix is also presenting an oral abstract titled “ Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone .”This first-ever oral abstract for Corgenix will be discussed at 11:30 a.m. during the AACC morning symposia titled “ Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections .”
The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
SOURCE: Corgenix Medical Corporation
Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
303-453-8903
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor
303-623-1190 x230
dan@armadamedical.com
Copyright Business Wire 2014
$CONX - Corgenix Medical Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Ebola research award and Lassa fever oral abstract highlight Corgenix infectious disease diagnostic test development capabilities
CHICAGO, Jul 30, 2014 (BUSINESS WIRE) -- Corgenix Medical Corporation CONX+4.76% has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract “ Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection ,” presented at the conference by Corgenix Research Associate Abby Jones, M.S.
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point of Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.
“We’re pleased to accept this prestigious award, and we must also recognize our academic, research and industry partners at the Viral Hemorrhagic Fever Consortium who have helped to make this possible,” said Douglass Simpson, Corgenix President and CEO. “We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats.”
Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV® rapid diagnostic test for the Lassa fever virus.
Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it’s clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg.
On Thursday, July 31, 2014, Corgenix is also presenting an oral abstract titled “ Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone .”This first-ever oral abstract for Corgenix will be discussed at 11:30 a.m. during the AACC morning symposia titled “ Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections .”
The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
SOURCE: Corgenix Medical Corporation
Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
303-453-8903
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor
303-623-1190 x230
dan@armadamedical.com
Copyright Business Wire 2014
$IMSC - Implant Sciences Reached a New 52 Week High at $1.24
Alert Triggered for Implant Sciences Corp
IMSC rose 6.81% to a new 52 week high of $1.24. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.24.
Additionally, over the last 12 months, IMSC has increased 7.74% while its peers in the Electronic Equipment & Instruments industry increased 12.15%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
Edit: New 52 Week High at $1.28
$IMSC - Implant Sciences Reached a New 52 Week High at $1.24
Alert Triggered for Implant Sciences Corp
IMSC rose 6.81% to a new 52 week high of $1.24. During the last 52 weeks, IMSC's price has ranged from $0.72 on February 14, 2014 to today's high of $1.24.
Additionally, over the last 12 months, IMSC has increased 7.74% while its peers in the Electronic Equipment & Instruments industry increased 12.15%.
Please note you will receive only one "New 52 Week High" alert per day for Implant Sciences Corp.
Edit: New 52 Week High at $1.28
$IMSC - Implant Sciences Volume Alert Triggered
IMSC's Trading Volume Exceeded Daily Average by +234.65%
IMSC is up $0.04 or 3.45% to $1.20 on heavy volume that exceeded its daily average by +234.65%. This performance is better than the broader averages as the S&P 500 is up +0.24% on the day.
Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Implant Sciences Corp.
$IMSC - Implant Sciences Volume Alert Triggered
IMSC's Trading Volume Exceeded Daily Average by +234.65%
IMSC is up $0.04 or 3.45% to $1.20 on heavy volume that exceeded its daily average by +234.65%. This performance is better than the broader averages as the S&P 500 is up +0.24% on the day.
Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Implant Sciences Corp.
Industry News:
FLIR Systems Inc.: Oppenheimer starts with "outperform"
** Maker of thermal imaging systems' shares up 3 percent at $33.49
** Oppenheimer starts coverage of stock with "outperform" rating
CNBC Breaking News: Malaysia Airlines says it has lost contact with MH17; AP quotes Ukraine gov't advisor saying a plane has been shot down.
$IMSC - Implant Sciences nabs $550,000 in new ETD contracts:
http://www.prnewswire.com/news-releases/267473261.html
$IMSC - Implant Sciences nabs $550,000 in new ETD contracts:
http://www.prnewswire.com/news-releases/267473261.html
$IMSC - Implant Sciences new application of checkpoint vehicle screening for explosive trace detection:
$IMSC - Implant Sciences new application of checkpoint vehicle screening for explosive trace detection:
$IMSC - Implant Sciences new application of checkpoint vehicle screening for explosive trace detection:
$IMSC - Implant Sciences new application of checkpoint vehicle screening for explosive trace detection:
$CONX - Corgenix Medical to develop research test kit in support of new diabetes test
DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus' U.S. and European Union commercialization programs. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.
"We're pleased to be working with Mellitus on this groundbreaking project," said Douglass Simpson, Corgenix President and CEO. "This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization."
"Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix' in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test," said Joyce A. Lonergan, Mellitus CEO and co-founder.
About Mellitus LLC
Mellitus is a private company that was founded to develop and commercialize a novel in vitro diagnostic assay for the measurement of Glycated CD59 (GCD59). GCD59 may provide information about glycemic control, with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a companion diagnostic for pharmaceutical development. Mellitus' lead product candidate is an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM). The GCD59 technology is based on research conducted by Drs. Jose Halperin and Michael Chorev at Harvard Medical School. The technology is part of a patent portfolio exclusively licensed to Mellitus. Mellitus is located in Cambridge, Massachusetts.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world's only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: Corgenix Medical Corp. William Critchfield, 303-453-8903 Senior VP Operations and Finance and CFO wcritchfield@corgenix.com or Mellitus, LLC Joyce A. Lonergan, 617-758-4146 CEO and co-founder jlonergan@mellitusllc.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x230 Vice President and Public Relations Supervisor dan@armadamedical.com Source: Corgenix Medical
$CONX - Corgenix Medical to develop research test kit in support of new diabetes test
DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus' U.S. and European Union commercialization programs. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.
"We're pleased to be working with Mellitus on this groundbreaking project," said Douglass Simpson, Corgenix President and CEO. "This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization."
"Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix' in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test," said Joyce A. Lonergan, Mellitus CEO and co-founder.
About Mellitus LLC
Mellitus is a private company that was founded to develop and commercialize a novel in vitro diagnostic assay for the measurement of Glycated CD59 (GCD59). GCD59 may provide information about glycemic control, with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a companion diagnostic for pharmaceutical development. Mellitus' lead product candidate is an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM). The GCD59 technology is based on research conducted by Drs. Jose Halperin and Michael Chorev at Harvard Medical School. The technology is part of a patent portfolio exclusively licensed to Mellitus. Mellitus is located in Cambridge, Massachusetts.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world's only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: Corgenix Medical Corp. William Critchfield, 303-453-8903 Senior VP Operations and Finance and CFO wcritchfield@corgenix.com or Mellitus, LLC Joyce A. Lonergan, 617-758-4146 CEO and co-founder jlonergan@mellitusllc.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x230 Vice President and Public Relations Supervisor dan@armadamedical.com Source: Corgenix Medical
$CONX - Corgenix Medical to develop research test kit in support of new diabetes test
DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus' U.S. and European Union commercialization programs. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.
"We're pleased to be working with Mellitus on this groundbreaking project," said Douglass Simpson, Corgenix President and CEO. "This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization."
"Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix' in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test," said Joyce A. Lonergan, Mellitus CEO and co-founder.
About Mellitus LLC
Mellitus is a private company that was founded to develop and commercialize a novel in vitro diagnostic assay for the measurement of Glycated CD59 (GCD59). GCD59 may provide information about glycemic control, with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a companion diagnostic for pharmaceutical development. Mellitus' lead product candidate is an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM). The GCD59 technology is based on research conducted by Drs. Jose Halperin and Michael Chorev at Harvard Medical School. The technology is part of a patent portfolio exclusively licensed to Mellitus. Mellitus is located in Cambridge, Massachusetts.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world's only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: Corgenix Medical Corp. William Critchfield, 303-453-8903 Senior VP Operations and Finance and CFO wcritchfield@corgenix.com or Mellitus, LLC Joyce A. Lonergan, 617-758-4146 CEO and co-founder jlonergan@mellitusllc.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x230 Vice President and Public Relations Supervisor dan@armadamedical.com Source: Corgenix Medical
$CONX - Corgenix Medical to develop research test kit in support of new diabetes test
DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus' U.S. and European Union commercialization programs. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.
"We're pleased to be working with Mellitus on this groundbreaking project," said Douglass Simpson, Corgenix President and CEO. "This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization."
"Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix' in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test," said Joyce A. Lonergan, Mellitus CEO and co-founder.
About Mellitus LLC
Mellitus is a private company that was founded to develop and commercialize a novel in vitro diagnostic assay for the measurement of Glycated CD59 (GCD59). GCD59 may provide information about glycemic control, with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a companion diagnostic for pharmaceutical development. Mellitus' lead product candidate is an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM). The GCD59 technology is based on research conducted by Drs. Jose Halperin and Michael Chorev at Harvard Medical School. The technology is part of a patent portfolio exclusively licensed to Mellitus. Mellitus is located in Cambridge, Massachusetts.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world's only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: Corgenix Medical Corp. William Critchfield, 303-453-8903 Senior VP Operations and Finance and CFO wcritchfield@corgenix.com or Mellitus, LLC Joyce A. Lonergan, 617-758-4146 CEO and co-founder jlonergan@mellitusllc.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x230 Vice President and Public Relations Supervisor dan@armadamedical.com Source: Corgenix Medical
Corgenix to develop research test kit in support of new diabetes test
DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus' U.S. and European Union commercialization programs. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.
"We're pleased to be working with Mellitus on this groundbreaking project," said Douglass Simpson, Corgenix President and CEO. "This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization."
"Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix' in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test," said Joyce A. Lonergan, Mellitus CEO and co-founder.
About Mellitus LLC
Mellitus is a private company that was founded to develop and commercialize a novel in vitro diagnostic assay for the measurement of Glycated CD59 (GCD59). GCD59 may provide information about glycemic control, with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a companion diagnostic for pharmaceutical development. Mellitus' lead product candidate is an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM). The GCD59 technology is based on research conducted by Drs. Jose Halperin and Michael Chorev at Harvard Medical School. The technology is part of a patent portfolio exclusively licensed to Mellitus. Mellitus is located in Cambridge, Massachusetts.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world's only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: Corgenix Medical Corp. William Critchfield, 303-453-8903 Senior VP Operations and Finance and CFO wcritchfield@corgenix.com or Mellitus, LLC Joyce A. Lonergan, 617-758-4146 CEO and co-founder jlonergan@mellitusllc.com or Media Contact: Armada Medical Marketing Dan Snyders, 303-623-1190 x230 Vice President and Public Relations Supervisor dan@armadamedical.com Source: Corgenix Medical Corporation
That's what makes Implant Sciences the most trusted name in explosive trace detection IMHO.
$IMSC - Implant Sciences prints new 2014 high of 1.19.
$IMSC - Implant Sciences prints new 2014 high of 1.19.
$IMSC - Implant Sciences prints new 2014 high of 1.19.
$IMSC - Implant Sciences prints new 2014 high of 1.19.